Uracil API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Uracil | CAS No: 66-22-8 | GMP-certified suppliers
A medication that serves as a fundamental pyrimidine base in RNA research and investigational oncology applications, supporting development of antimetabolite therapies and nucleic acid-related drug synthesis.
Therapeutic categories
Product Snapshot
- Uracil is available as an oral capsule formulation
- It is primarily used in investigational settings related to metabolic and chemotherapeutic applications
- Uracil is currently classified as experimental with no confirmed approvals in major regulatory markets
Clinical Overview
Currently, uracil is primarily utilized in experimental and investigational contexts and does not have approved clinical indications as a standalone pharmaceutical agent. It is related chemically to a class of compounds that includes fluorouracil and its prodrugs, which are well-established antimetabolite agents used in oncology. However, uracil itself lacks formally recognized pharmacodynamics or defined mechanism of action data relevant for therapeutic use.
Pharmacokinetic profiles specific to uracil are not extensively documented in clinical literature. As a naturally occurring pyrimidine base, uracil is known to participate in nucleic acid metabolism, including incorporation into RNA and cellular enzymatic pathways involving pyrimidine salvage and synthesis. Absorption, distribution, metabolism, and excretion characteristics in pharmaceutical formulations remain under investigation.
Safety and toxicity data on uracil as a drug substance are limited. Given its endogenous nature, it is generally regarded as having low inherent toxicity; however, potential interactions or effects related to elevated exogenous exposure warrant further evaluation within experimental settings.
Notable pharmaceutical uses predominantly involve derivatives of uracil, such as fluorouracil, which serve as chemotherapeutic agents. Uracil itself does not have widely recognized branded products or formalized clinical applications.
For API sourcing, procuring uracil necessitates attention to purity specifications consistent with nucleobase standards, including impurity profiling and microbial limits. Regulatory compliance and traceability are critical, especially when sourced for investigational use or as a precursor in drug synthesis. Manufacturers should provide detailed certificates of analysis and adhere to established Good Manufacturing Practices to ensure quality and reproducibility in pharmaceutical development.
Identification & chemistry
| Generic name | Uracil |
|---|---|
| Molecule type | Small molecule |
| CAS | 66-22-8 |
| UNII | 56HH86ZVCT |
| DrugBank ID | DB03419 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Dihydropyrimidine dehydrogenase [NADP(+)] | Humans | |
| Uridine-cytidine kinase-like 1 | Humans | |
| Uracil-DNA glycosylase | HHV-1 |
Formulation & handling
- Uracil is a small molecule suitable for oral administration, primarily formulated as capsules.
- Due to its low LogP and high water solubility, it demonstrates good aqueous compatibility in formulations.
- No specific peptide or biologic handling considerations apply; stability data should be reviewed for formulation optimization.
Regulatory status
Uracil is a type of Antineoplastics
Antineoplastics are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) primarily used in the treatment of cancer. These powerful substances inhibit or destroy the growth of cancer cells, thus impeding the progression of malignancies.
Antineoplastics exert their therapeutic effects through various mechanisms. Some APIs interfere with DNA replication, inhibiting the division and proliferation of cancer cells. Others target specific proteins or enzymes involved in tumor growth, effectively blocking their function. Additionally, certain antineoplastic agents induce programmed cell death, known as apoptosis, in cancer cells.
These APIs find application in a wide range of cancer treatments, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy. They are often administered in combination with other drugs to optimize therapeutic outcomes and minimize drug resistance.
Antineoplastics are typically synthesized through complex chemical processes, ensuring high purity and potency. Stringent quality control measures are implemented throughout manufacturing to meet regulatory standards and ensure patient safety.
Although antineoplastics offer significant benefits in treating cancer, they can also cause adverse effects due to their cytotoxic nature. Common side effects include bone marrow suppression, gastrointestinal disturbances, hair loss, and immune system suppression. Close monitoring and supportive care are essential to manage these side effects effectively.
In conclusion, antineoplastics are a vital category of pharmaceutical APIs used in the treatment of cancer. Through their diverse mechanisms of action, these compounds play a critical role in combating malignancies and improving patient outcomes.
